

April 30, 2004

NOTE TO: Division of Dockets Management (HFA-305)

SUBJECT: Docket No. 2004N-0087; Generic Drug Issues; Request for Comments

Please include this note in docket number 2004N-0087. See 21 CFR 10.40 (b)(3).

This note confirms that the comment period for the subject docket which was scheduled to close on May 3, 2004 will be kept open for two more days until May, 5, 2004. The extension of less than 30 days is granted to allow Kathleen D. Jaeger, President and CEO of the Generic Pharmaceutical Association to submit comments to the subject docket.

Edwin V. Dutra, Jr.

Director, Regulations Policy and Management Staff, HF-26

g:\rpms\wp\ed\04n-0087.wpd